From: Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma
Parameters
DRd group
KRd group
Increment
Cost
15,370
15,106
264
QALY
1.56
1.28
0.28
lYG
5.86
3.52
2.34
ICUR
–
956
ICER
472
ACER
9859
11,773
NMB
− 13,359
− 13,451
92